OSI to benefit from uses for cancer drug-Barron's

NEW YORK, July 26 (Reuters) - OSI Pharmaceuticals OSIP.O shares could benefit as the Melville, N.Y.-based company expands the uses of its lung-cancer drug, Barron's said.

OSI's sales of Tarceva, the second-largest oral anti-cancer drug, hit $1 billion last year.

OSI trades for about $32 a share, about 18 times next year's earnings, Barron's said, projecting it could rally to $45 a share in the coming year with the help of Tarceva. (Reporting by Steve Eder)